<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">The Clinician</journal-id><journal-title-group><journal-title xml:lang="en">The Clinician</journal-title><trans-title-group xml:lang="ru"><trans-title>Клиницист</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1818-8338</issn><issn publication-format="electronic">2412-8775</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">525</article-id><article-id pub-id-type="doi">10.17650/1818-8338-2023-17-1-K675</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>REVIEW</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОБЗОР</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Risk factors and diagnostic markers for acute coronary syndrome in chronic kidney disease</article-title><trans-title-group xml:lang="ru"><trans-title>Факторы риска и диагностические маркеры острого коронарного синдрома при хронической болезни почек</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6129-0625</contrib-id><name-alternatives><name xml:lang="en"><surname>Kamyshnikova</surname><given-names>L. A.</given-names></name><name xml:lang="ru"><surname>Камышникова</surname><given-names>Л. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Lyudmila Aleksandrovna Kamyshnikova </p><p>85 Pobedy St., Belgorod 308015</p></bio><bio xml:lang="ru"><p>Людмила Александровна Камышникова</p><p>308015 Белгород, ул. Победы, 85</p></bio><email>kamyshnikova@bsu.edu.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3106-8900</contrib-id><name-alternatives><name xml:lang="en"><surname>Pisankina</surname><given-names>D. S.</given-names></name><name xml:lang="ru"><surname>Писанкина</surname><given-names>Д. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>85 Pobedy St., Belgorod 308015</p></bio><bio xml:lang="ru"><p>308015 Белгород, ул. Победы, 85</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2650-1738</contrib-id><name-alternatives><name xml:lang="en"><surname>Gorbachevskaya</surname><given-names>K. S.</given-names></name><name xml:lang="ru"><surname>Горбачевская</surname><given-names>К. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>85 Pobedy St., Belgorod 308015</p></bio><bio xml:lang="ru"><p>308015 Белгород, ул. Победы, 85</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4948-3715</contrib-id><name-alternatives><name xml:lang="en"><surname>Biryukov</surname><given-names>G. V.</given-names></name><name xml:lang="ru"><surname>Бирюков</surname><given-names>Г. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>85 Pobedy St., Belgorod 308015</p></bio><bio xml:lang="ru"><p>308015 Белгород, ул. Победы, 85</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3898-1417</contrib-id><name-alternatives><name xml:lang="en"><surname>Sviridova</surname><given-names>M. S.</given-names></name><name xml:lang="ru"><surname>Свиридова</surname><given-names>М. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>85 Pobedy St., Belgorod 308015</p></bio><bio xml:lang="ru"><p>308015 Белгород, ул. Победы, 85</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8334-2967</contrib-id><name-alternatives><name xml:lang="en"><surname>Kalashnikova</surname><given-names>I. V.</given-names></name><name xml:lang="ru"><surname>Калашникова</surname><given-names>И. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>85 Pobedy St., Belgorod 308015</p></bio><bio xml:lang="ru"><p>308015 Белгород, ул. Победы, 85</p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Belgorod State National Research University, Ministry of Education and Science of Russia</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВО «Белгородский государственный национальный исследовательский университет»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2023-01-15" publication-format="electronic"><day>15</day><month>01</month><year>2023</year></pub-date><volume>17</volume><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>21</fpage><lpage>27</lpage><history><date date-type="received" iso-8601-date="2023-08-10"><day>10</day><month>08</month><year>2023</year></date><date date-type="accepted" iso-8601-date="2023-08-10"><day>10</day><month>08</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2023, Kamyshnikova L.A., Pisankina D.S., Gorbachevskaya K.S., Biryukov G.V., Sviridova M.S., Kalashnikova I.V.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2023, Камышникова Л.А., Писанкина Д.С., Горбачевская К.С., Бирюков Г.В., Свиридова М.С., Калашникова И.В.</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="en">Kamyshnikova L.A., Pisankina D.S., Gorbachevskaya K.S., Biryukov G.V., Sviridova M.S., Kalashnikova I.V.</copyright-holder><copyright-holder xml:lang="ru">Камышникова Л.А., Писанкина Д.С., Горбачевская К.С., Бирюков Г.В., Свиридова М.С., Калашникова И.В.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://klinitsist.abvpress.ru/Klin/article/view/525">https://klinitsist.abvpress.ru/Klin/article/view/525</self-uri><abstract xml:lang="en"><p><bold>Introduction.</bold> Acute coronary artery disease is the leading cause of death in patients with chronic kidney disease (CKD). In addition, CKD itself is the initiator of acute coronary syndrome (ACS), the prevalence of which is greater, the more pronounced the impairment of kidney function and the more concomitant risk factors in the patient.</p><p><bold>Aim.</bold> To study the predictive value of various laboratory and instrumental markers in identifying the risk of developing ACS in patients with CKD.</p><p><bold>Materials and methods.</bold> A search was made for articles for the last 10 years in the databases: PubMed, Medline, Google Scholar and eLIBRARY by keywords in Russian and English, the articles were selected in accordance with the purpose of the study.</p><p><bold>Results.</bold> ACS manifests itself in CKD patients with an atypical picture, and in 3 % of cases it is generally asymptomatic. The risk of death from cardiovascular complications increases in proportion to the deterioration of the glomerular  filtration rate (GFR). This progression also increases the risk of coronary artery calcification. At the same time, it was found that cystatin C is a more universal marker of a decrease in GFR than creatinine. Other laboratory markers that indicate the risk of ACS are inflammatory markers, albuminuria, troponins, natriuretic peptide.</p><p><bold>Conclusion.</bold> So far as ACS is atypical or asymptomatic, in addition to troponins and traditional instrumental diagnostic methods, markers such as GFR, albuminuria, an increase in serum cystatin C, phosphate, fibroblast growth factor-23, interleukin-6, tumor necrosis factor-alpha, total parathyroid hormone, fibrinogen, natriuretic peptide can help in its prediction.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Введение. </bold>Острые формы ишемической болезни сердца признаны основной причиной смерти у пациентов с хро­нической болезнью почек (Хбп). Кроме того, Хбп сама инициирует развитие острого коронарного синдрома (ОКС), распространенность которого тем выше, чем более выражено нарушение функции почек и чем больше сопутству­ющих факторов риска у больного.</p><p><bold>Цель исследования </bold>- изучение прогностической ценности различных лабораторных и инструментальных маркеров в выявлении риска развития ОКС у больных Хбп.</p><p><bold>Материалы и методы. </bold>проведен поиск статей за последние 10 лет в базах PubMed, Medline, Google Scholar и eLIBRARY по ключевым словам на русском и английском языках в соответствии с целью исследования.</p><p><bold>Результаты. </bold>ОКС манифестирует атипичной картиной у больных Хбп, а в 3 % случаев - вообще бессимптомно. Риск смерти от сердечно-сосудистых осложнений возрастает пропорционально снижению скорости клубочковой филь­трации (СКф). Данная прогрессия также увеличивает риск кальцификации коронарных артерий. при этом выявле­но, что цистатин С - более универсальный маркер снижения СКф, чем креатинин. Другими лабораторными марке­рами, указывающими на риск ОКС, выступают воспалительные маркеры, альбуминурия, натрийуретический пептид.</p><p><bold>Заключение. </bold>Так как ОКС может протекать атипично, то в его прогнозировании в клинических условиях, помимо тропонинов и традиционных инструментальных методов диагностики, могут играть роль такие маркеры, как СКф, альбуминурия, увеличение в сыворотке крови уровня цистатина С, фосфата, фактора роста фибробластов-23, ин­терлейкина-6, фактора некроза опухолей альфа, общего паратгормона, фибриногена, натрийуретического пептида. </p></trans-abstract><kwd-group xml:lang="en"><kwd>acute coronary syndrome</kwd><kwd>chronic kidney disease</kwd><kwd>coronary artery disease</kwd><kwd>markers</kwd><kwd>troponin</kwd><kwd>glomerular filtration rate</kwd><kwd>cystatin C</kwd><kwd>natriuretic peptide</kwd><kwd>interleukin-6</kwd><kwd>tumor necrosis factor alpha</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>острый коронарный синдром</kwd><kwd>хроническая болезнь почек</kwd><kwd>ишемическая болезнь сердца</kwd><kwd>маркеры</kwd><kwd>тропонин</kwd><kwd>скорость клубочковой фильтрации</kwd><kwd>цистатин С</kwd><kwd>натрийуретический пептид</kwd><kwd>интерлейкин-6</kwd><kwd>фактор некроза опухолей альфа</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">Ogryzko E.V., Ivanova M.A., Odinets A.V. et al. Dynamics of morbidity and mortality in the adult population with acute forms of coronary heart disease in the Russian Federation in 2012–2017. Profilakticheskaya Meditsina = Preventive medicine 2019;22(5):23–6. (In Russ.). DOI: 10/17116//profmed20192205123</mixed-citation><mixed-citation xml:lang="ru">Огрызко Е.В., Иванова М.А., Одинец А.В. и др. Динамика заболеваемости взрослого населения острыми формами ишемической болезни сердца и смертности от них в Российской Федерации в 2012–2017 гг. Профилактическая медицина 2019;22(5):23–6. DOI: 10/17116//profmed20192205123</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><mixed-citation>Sanchis J., Soler M., Núñez J. et al. Comorbidity assessment for mortality risk stratification in elderly patients with acute coronary syndrome. Eur J Intern Med 2019;62:48–53. DOI: 10.1016/j.ejim.2019.01.018</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Mayer O.J., Seidlerová J., Bruthans J. et al. The prognostic impact of renal function decline during hospitalization for myocardial infarction. J Comp Eff Res 2021;10(3):219–28. DOI: 10.2217/cer-2020-0085</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Tawfik A.M., Tawfik H.M. Nontraditional risk factors in chronic kidney disease: correlation between creatinine clearance, Framingham risk score, endothelial dysfunction, and inflammation. Egypt J Intern Med 2022;34:29. DOI: 10.1186/s43162-022-00110-2</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Moisi M.I., Rus M., Bungau S. et al. Acute Coronary syndromes in chronic kidney disease: clinical and therapeutic characteristics. Medicina (Kaunas) 2020;56(3):118. DOI: 10.3390/medicina56030118</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Hao Y., Liu J., Liu J. et al. Sex differences in in-hospital management and outcomes of patients with acute coronary syndrome. Circulation 2019;139(15):1776–85. DOI: 10.1161/CIRCULATIONAHA.118.037655</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Brar A., Markell M. Impact of gender and gender disparities in patients with kidney disease. Curr Opin Nephrol Hypertens 2019;28(2):178–82. DOI: 10.1097/MNH.0000000000000482</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Navarro M.A., Gosch K.L., Spertus J.A. et al. Chronic Kidney Review Disease and health status outcomes following acute myocardial infarction. J Am Heart Assoc 2016;5(5):e002772. DOI: 10.1161/JAHA.115.002772</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Chang Y.T., Liu C.C., Tsai L.M. et al. Separate and joint effects of diabetes mellitus and chronic kidney disease on the risk of acute coronary syndrome: a population-based cohort study. Medicine (Baltimore) 2014;93(28):e261. DOI: 10.1097/MD.0000000000000261</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Lawler P.R., Filion K.B., Dourian T. et al. Anemia and mortality in acute coronary syndromes: a systematic review and metaanalysis. Am Heart J 2013;165(2):143–53.e5. DOI: 10.1016/j.ahj.2012.10.024</mixed-citation></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">Kamyshnikova L.A., Efremova O.A., Pivovar R.S. Features of cardiorenal relationship at patients with the chronic disease of kidneys. Тhe current state of the problem. Nauchny’e vedomosti Belgorodskogo gosudarstvennogo universiteta. Seriya: Medicina. Farmaciya = Belgorod State University Scientific bulletin. Medicine. Pharmacy 2017;5:13–21. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Камышникова Л.А., Ефремова О.А., Пивовар Р.С. Особенности кардиоренальных взаимоотношений у больных с хронической болезнью почек. Современное состояние проблемы. Научные ведомости Белгородского государственного университета. Серия: Медицина. Фармация 2017;5:13–21.</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><mixed-citation>Beska B., Mills G.B., Ratcovich H. et al. Impact of multimorbidity on long-term outcomes in older adults with non-ST elevation acute coronary syndrome in the North East of England: a multi-centre cohort study of patients undergoing invasive care. BMJ open 2022;12(7):e061830. DOI: 10.1136/bmjopen-2022-061830</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Roy N., Rosas S.E. IL-6 is associated with progression of coronary artery calcification and mortality in incident dialysis patients. Am J Nephrol 2021;52(9):745–52. DOI: 10.1159/000518652</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Salvador-González B., Gil-Terrón N., Cerain-Herrero M.J. et al. Estimated glomerular filtration rate, cardiovascular events and mortality across age groups among individuals older than 60 years in Southern Europe. Rev Esp Cardiol (Engl Ed) 2018;71(6):450–7. DOI: 10.1016/j.rec.2017.09.010</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Efremova O.A., Kamyshnikova L.A., Obolonkova N.I. et al. Mechanisms of development of heart failure in chronic kidney disease. Challenges in Modern Medicine 2022;45(3):237–52. DOI: 10.52575/2687-0940-2022-45-3-237-252</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Sarnak M.J., Amann K., Bangalore S. et al.; Conference Participants. Chronic kidney disease and coronary artery disease: JACC state-of-the-art review. J Am Coll Cardiol 2019;74(14):1823–38. DOI: 10.1016/j.jacc.2019.08.1017</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Ballo P., Chechi T., Spaziani G. et al. Prognostic comparison between creatinine-based glomerular filtration rate formulas for the prediction of 10-year outcome in patients with non-ST elevation acute coronary syndrome treated by percutaneous coronary intervention. Eur Heart J Acute Cardiovasc Care 2018;7(8):689–702. DOI: 10.1177/2048872617697452</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Jaques D.A., Müller H., Martinez C. et al. Nondipping pattern on 24-h ambulatory blood pressure monitoring is associated with left ventricular hypertrophy in chronic kidney disease. Blood Press Monit 2018;23(5):244–52. DOI: 10.1097/MBP.0000000000000337</mixed-citation></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">Kamyshnikova L.А., Efremova O.A. Impact of comorbidities on myocardial remodeling and dysfunction in heart failure with preserved ejection fraction. Klinicheskaya Meditsina = Clinical medicine 2017;95(12):1070–6. (In Russ.). DOI: 10.18821/0023-2149-2017-95-12-1070-1076</mixed-citation><mixed-citation xml:lang="ru">Камышникова Л.А., Ефремова О.А. Влияние сопутствующих заболеваний на ремоделирование и дисфункцию сердца при хронической сердечной недостаточности с сохранной фракцией выброса. Клиническая медицина 2017;95(12):1070–6. DOI: 10.18821/0023-2149-2017-95-12-1070-1076</mixed-citation></citation-alternatives></ref><ref id="B20"><label>20.</label><mixed-citation>Nitta K., Iimuro S., Imai E. et al. Risk factors for increased left ventricular hypertrophy in patients with chronic kidney disease: findings from the CKD-JAC study. Clin Exp Nephrol 2019;23(1):85–98. DOI: 10.1007/s10157-018-1605-z</mixed-citation></ref><ref id="B21"><label>21.</label><citation-alternatives><mixed-citation xml:lang="en">Clinical practice guidelines for Acute ST-segment elevation myocardial infarction / Russian Society of Cardiology 2020. Rossijskij kardiologicheskij zhurnal = Russian Journal of Cardiology 2020;25(11):4103. (In Russ.). DOI: 10.15829/1560-4071-2020-4103</mixed-citation><mixed-citation xml:lang="ru">Острый инфаркт миокарда с подъемом сегмента ST электрокардиограммы. Клинические рекомендации 2020 / Российское кардиологическое общество. Российский кардиологический журнал 2020;25(11):4103. DOI: 10.15829/1560-4071-2020-4103 DOI: 10.15829/1560-4071-2020-4103</mixed-citation></citation-alternatives></ref><ref id="B22"><label>22.</label><mixed-citation>Bansal N., Hyre Anderson A., Yang W. et al. High-sensitivity troponin T and N-terminal pro-B-type natriuretic peptide (NT-proBNP) and risk of incident heart failure in patients with CKD: the Chronic Renal Insufficiency Cohort (CRIC) Study. J Am Soc Nephrol 2015;26(4):946–56. DOI: 10.1681/ASN.2014010108</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Guclu T., Bolat S., Şenes M. et al. Relationship between high sensitivity troponins and estimated glomerular filtration rate. Clin Biochem 2016;49(6):467–71. DOI: 10.1016/j.clinbiochem.2015.12.012</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Bansal N., Zelnick L.R., Ballantyne C.M. et al. Upper reference limits for high-sensitivity cardiac troponin T and N-terminal fragment of the prohormone brain natriuretic peptide in patients with CKD. Am J Kidney Dis 2022;79(3):383–92. DOI: 10.1053/j.ajkd.2021.06.017</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Cardinaels E.P., Daamen M.A., Bekers O. et al. Clinical interpretation of elevated concentrations of cardiac troponin T, but not troponin I, in nursing home residents. J Am Med Dir Assoc 2015;16(10):884–91. DOI: 10.1016/j.jamda.2015.06.026</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Sun L., Ji Y., Wang Y. et al. High-sensitive cardiac troponin T: a biomarker of left-ventricular diastolic dysfunction in hemodialysis patients. J Nephrol 2018;31(6):967–73. DOI: 10.1007/s40620-018-0540-0</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Arnadottir A., Vestergaard K.R., Pallisgaard J. et al. High-sensitivity cardiac troponin T is superior to troponin I in the prediction of mortality in patients without acute coronary syndrome. Int J Cardiol 2018;259:186–91. DOI: 10.1016/j.ijcard.2018.01.131</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Buiten M.S., de Bie M.K., Rotmans J.I. et al. Serum cardiac troponin-I is superior to troponin-T as a marker for left ventricular dysfunction in clinically stable patients with end-stage renal disease. PloS One 2015;10(8):e0134245. DOI: 10.1371/journal.pone.0134245</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Bansal N., Zelnick L.R., Soliman E.Z. et al. Change in cardiac biomarkers and risk of incident heart failure and atrial fibrillation in ckd: the Chronic Renal Insufficiency Cohort (CRIC) study. Am J Kidney Dis 2021;77(6):907–19. DOI: 10.1053/j.ajkd.2020.09.021</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Colbert G., Jain N., de Lemos J.A. et al. Utility of traditional circulating and imaging-based cardiac biomarkers in patients with predialysis CKD. Clin J Am Soc Nephrol 2015;10(3):515–29. DOI: 10.2215/CJN.03600414</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Kampmann J., Heaf J., Backer Mogensen C. et al. Troponin cutoffs for acute myocardial infarction in patients with impaired renal function – a systematic review and meta-analysis. Diagnostics 2022;12(2):276. DOI: 10.3390/diagnostics12020276</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Sundqvist S., Larson T., Cauliez B. et al. Clinical value of natriuretic peptides in predicting time to dialysis in stage 4 and 5 chronic kidney disease patients. PLoS One 2016;11(8):e0159914. DOI: 10.1371/journal.pone.0159914</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Park M., Hsu C.Y., Go A.S. et al. Urine kidney injury biomarkers and risks of cardiovascular disease events and all-cause death: the CRIC study. Clin J Am Soc Nephrol 2017;12(5):761–71. DOI: 10.2215/CJN.08560816</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Wang K., Ni G., Wu Q. et al. Prognostic value of n-terminal Pro-B-type natriuretic peptide and glomerular filtration rate in patients with acute heart failure. Front Cardiovasc Med 2020;7:123. DOI: 10.3389/fcvm.2020.00123</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Vinnakota S., Scott C.G., Rodeheffer R.J. et al. Estimated glomerular filtration rate, activation of cardiac biomarkers and long-term cardiovascular outcomes: a population-based cohort. Mayo Clin Proc 2019;94(11):2189–98. DOI: 10.1016/j.mayocp.2019.03.033</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Aimo A., Januzzi J.L. Jr, Vergaro G. et al. High-sensitivity troponin T, NT-proBNP and glomerular filtration rate: A multimarker strategy for risk stratification in chronic heart failure. Int J Cardiol 2019;277:166–72. DOI: 10.1016/j.ijcard.2018.10.079</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Schlieper G. Vascular calcification in chronic kidney disease: not all arteries are created equal. Kidney Int 2014;85(3):501–3. DOI: 10.1038/ki.2013.423</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Nichols G.A., Déruaz-Luyet A., Hauske S.J. et al. The association between estimated glomerular filtration rate, albuminuria, and risk of cardiovascular hospitalizations and all-cause mortality among patients with type 2 diabetes. J Diabetes Complications 2018:32(3):291–7. DOI: 10.1016/j.jdiacomp.2017.12.003</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Kühn A., van der Giet M., Kuhlmann M.K. et al. Kidney function as risk factor and predictor of cardiovascular outcomes and mortality among older adults. Am J Kidney Dis 2021;77(3):386–96. e1. DOI: 10.1053/j.ajkd.2020.09.015</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Ishigami J., Grams M.E., Naik R.P. et al. hemoglobin, albuminuria, and kidney function in cardiovascular risk: The ARIC (Atherosclerosis Risk in Communities) study. J Am Heart Assoc 2018;7(2):e007209. DOI: 10.1161/JAHA.117.007209</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Scialla J.J., Xie H., Rahman M. et al. Fibroblast growth factor-23 and cardiovascular events in CKD. J Am Soc Nephrol 2014;25(2):349–60. DOI: 10.1681/ASN.2013050465</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Hyun Y.Y., Kim H., Oh Y.K. et al. High fibroblast growth factor 23 is associated with coronary calcification in patients with high adiponectin: analysis from the KoreaN cohort study for Outcome in patients With Chronic Kidney Disease (KNOW-CKD) study. Nephrol Dial Transplant 2019;34(1):123–9. DOI: 10.1093/ndt/gfy110</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Krishnasamy R., Tan S.J., Hawley C.M. et al. Progression of arterial stiffness is associated with changes in bone mineral markers in advanced CKD. BMC Nephrol 2017;18(1):281. DOI: 10.1186/s12882-017-0705-4</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Balmukhanova A., Kabulbayev K., Alpay H. et al. FGF-23 and Phosphate in children with chronic kidney disease: a cross-sectional study in Kazakhstan. Medicina (Kaunas) 2020;57(1):15. DOI: 10.3390/medicina57010015/</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>Isakova T., Cai X., Lee J. et al. Longitudinal evolution of markers of mineral metabolism in patients with ckd: the Chronic Renal Insufficiency Cohort (CRIC) study. Am J Kidney Dis 2020;75(2):235–44. DOI: 10.1053/j.ajkd.2019.07.022</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>Hari P., Ramakrishnan L., Gupta R. et al. Cystatin C-based glomerular filtration rate estimating equations in early chronic kidney disease. Indian Pediatr 2014;51(4):273–7. DOI: 10.1007/s13312-014-0400-5</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>Khalid U.B., Haroon Z.H., Aamir M. et al. Comparison of estimated glomerular filtration rate with both serum creatinine and cystatin C (eGFRcr-cys) versus single analyte (eGFRcr or eGFRcys) using CKD-EPI and MDRD equations in tertiary care hospital settings. J Coll Physicians Surg Pak 2020;30(7):701–6. DOI: 10.29271/jcpsp.2020.07.701</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation>Rothenbacher D., Rehm M., Iacoviello L. et al. Contribution of cystatin C- and creatinine-based definitions of chronic kidney disease to cardiovascular risk assessment in 20 population-based and 3 disease cohorts: the BiomarCaRE project. BMC Med 2020;18(1):300. DOI: 10.1186/s12916-020-01776-7</mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation>Matsushita K., Coresh J., Sang Y. et al. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. Lancet Diabetes Endocrinol 2015;3(7):514–25. DOI: 10.1016/S2213-8587(15)00040-6</mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation>Huang M.J., Wei R.B., Zhao J. et al. Albuminuria and endothelial dysfunction in patients with non-diabetic chronic kidney disease. Med Sci Monit 2017;23:4447–53. DOI: 10.12659/msm.903660</mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation>Ekart R., Šegula A., Hartman T. et al. Subendocardial viability ratio is impaired in highly proteinuric chronic kidney disease patients with low estimated glomerular filtration rate. Ther Apher Dial 2016;20(3):281–5. DOI: 10.1111/1744-9987.12438</mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation>Fung C.S., Wan E.Y., Chan A.K., Lam C.L. Association of estimated glomerular filtration rate and urine albumin-tocreatinine ratio with incidence of cardiovascular diseases and mortality in chinese patients with type 2 diabetes mellitus – a population-based retrospective cohort study. BMC Nephrol 2017;18(1):47. DOI: 10.1186/s12882-017-0468-y</mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation>Oshima M., Neuen B.L., Li J. et al. Early change in albuminuria with canagliflozin predicts kidney and cardiovascular outcomes: A PostHoc analysis from the CREDENCE trial. J Am Soc Nephrol 2020;31(12):2925–36. DOI: 10.1681/ASN.2020050723</mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation>Ishigami J., Grams M.E., Naik R.P. et al. Hemoglobin, albuminuria, and kidney function in cardiovascular risk: The ARIC (Atherosclerosis Risk in Communities) study. J Am Heart Assoc 2018;7(2):e007209. DOI: 10.1161/JAHA.117.007209</mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation>Batra G., Ghukasyan Lakic T., Lindbäck J. et al. STABILITY Investigators. Interleukin 6 and cardiovascular outcomes in patients with chronic kidney disease and chronic coronary syndrome. JAMA Cardiol 2021;6(12):1440–5. DOI: 10.1001/jamacardio.2021.3079</mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation>Roy N., Rosas S.E. IL-6 is associated with progression of coronary artery calcification and mortality in incident dialysis patients. Am J Nephrol 2021;52(9):745–52. DOI: 10.1159/000518652</mixed-citation></ref><ref id="B57"><label>57.</label><mixed-citation>Mukai H., Dai L., Chen Z. et al. Inverse J-shaped relation between coronary arterial calcium density and mortality in advanced chronic kidney disease. Nephrol Dial Transplant 2020;35(7):1202–11. DOI: 10.1093/ndt/gfy352</mixed-citation></ref><ref id="B58"><label>58.</label><mixed-citation>Kurozumi A., Nakano K., Yamagata K. et al. IL-6 and sIL-6R induces STAT3-dependent differentiation of human VSMCs into osteoblast-like cells through JMJD2B-mediated histone demethylation of RUNX2. Bone 2019;124:53–61. DOI: 10.1016/j.bone.2019.04.006</mixed-citation></ref><ref id="B59"><label>59.</label><mixed-citation>Fukuyo S., Yamaoka K., Sonomoto K. et al. IL-6-accelerated calcification by induction of ROR2 in human adipose tissue-derived mesenchymal stem cells is STAT3 dependent. Rheumatology (Oxford) 2014;53(7):1282–90. DOI: 10.1093/rheumatology/ket496</mixed-citation></ref><ref id="B60"><label>60.</label><mixed-citation>Wang X.R., Yuan L., Shi R. et al. Predictors of coronary artery calcification and its association with cardiovascular events in patients with chronic kidney disease. Ren Fail 2021;43(1):1172–9. DOI: 10.1080/0886022X.2021.1953529</mixed-citation></ref><ref id="B61"><label>61.</label><mixed-citation>Sun J., Axelsson J., Machowska A. et al. Biomarkers of Cardiovascular Disease and Mortality Risk in Patients with Advanced CKD. Clin J Am Soc Nephrol 2016;11(7):1163–72. DOI: 10.2215/CJN.10441015</mixed-citation></ref></ref-list></back></article>
